Investigators also examined which type of immunosuppression was associated with a higher likelihood of Kaposi sarcoma.
Findings presented at this month’s National Comprehensive Cancer Network (NCCN) annual conference show a significant gender disparity in who is likely to develop Kaposi sarcoma (KS) following a kidney transplant.1
Male recipients were found to be more susceptible to this cancer, which is caused by human herpesvirus-8 (HHV-8) and can appear after patients receive immunosuppressive therapy to avoid rejecting the donor kidney.
KS is characterized by purple, red, and brown tumors or lesions that appear on the skin, often on the legs or face, which develop from cells that line lymph or blood vessels. Tumors can also appear elsewhere in the body, such as the lymph nodes, the lungs, or digestive tract.
An earlier version of the NCCN results appeared in Cureus; those findings also highlighted a greater likelihood of KS to appear among recipients of African or Middle Eastern descent.2
That article explained how KS emerges and its particular threat to patients receiving a new kidney. “The intricate link between the HHV-8 virus and the immune system has been articulated as the key mechanism in the genesis of KS, with the malignancy observed in immunosuppressed patients as a result of acquired immunodeficiency syndrome (AIDS) infection or organ transplants,” the authors wrote.
“A kidney transplant requires a delicate balance between immunosuppression to decrease the likelihood of graft rejection while controlling for increased susceptibility to viral infection at the same time,” they continued. Thus, KS incidence is “closely associated with the duration and intensity of immunosuppression among kidney transplant patients, especially in patients where HHV-8 serology is present pre-transplantation.”
The review, led by Sakditad Saowapa, MD, a current resident at Texas Tech University Health Sciences Center, captured 15 studies involving 323 patients diagnosed with KS, from the PubMed, Google Scholar, and Cochrane Library databases. The review found the following:
“These findings underscore the importance of personalized immunosuppressive strategies and close monitoring of kidney transplant patients for KS, particularly among high-risk groups, to mitigate the incidence and improve outcomes of KS in this vulnerable population,” the authors wrote in the NCCN abstract.
References
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More